PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma
During the last two decades individualization of programmed treatment combined with intensified chemotherapy has proven to be effective treatment for the majority of classical Hodgkin’s lymphoma (cHL) patients. However, in 10–30 % of cases relapses and resistance to therapy still occur. Further inte...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2018-07-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: | http://bloodjournal.ru/wp-content/uploads/2018/06/1-5.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850242227096256512 |
|---|---|
| author | EA Demina |
| author_facet | EA Demina |
| author_sort | EA Demina |
| collection | DOAJ |
| description | During the last two decades individualization of programmed treatment combined with intensified chemotherapy has proven to be effective treatment for the majority of classical Hodgkin’s lymphoma (cHL) patients. However, in 10–30 % of cases relapses and resistance to therapy still occur. Further intensification of therapy induces toxicity that leads to decrease in overall survival and quality of life. The standard second-line treatment with high-dose chemotherapy (HDCT) and autologous hematopoietic stem cell transplantation (auto-HSCT) allows for the achievement of long-term 5-year progression-free survival only in 50–60 % of patients with relapsed disease and not more than 40–45 % of patients with refractory disease. Approximately 50 % of patients relapse after HDCT and auto-HSCT. The median overall survival of relapsed patients does not exceed 2 years. Allogeneic HSCT improves treatment results to some extent, but is not an optimal strategy in all patients. A search for new treatment options has been made to improve effectiveness of relapsed and refractory cHL treatment and to reduce toxicity of highly effective programs. А new CD30-targeted conjugate brentuximab vedotin was developed to use anti-CD30 monoclonal antibodies against a specific marker of tumor Reed-Sternberg cells allowing for the transfer of the highly effective antitumor compound of monomethyl auristatin E directly to tumor cells. This drug showed high effectiveness, although failed to provide a complete solution to the problem. The development of anti-PD1 antibody nivolumab opened up new opportunities for cHL treatment. This paper reviews literature information on pharmacological data and antitumor mechanisms of the drug as well as the results of significant international randomised studies. |
| format | Article |
| id | doaj-art-b582261119db47529e1dc0671fdf686a |
| institution | OA Journals |
| issn | 1997-6933 2500-2139 |
| language | Russian |
| publishDate | 2018-07-01 |
| publisher | Practical Medicine Publishing House |
| record_format | Article |
| series | Клиническая онкогематология |
| spelling | doaj-art-b582261119db47529e1dc0671fdf686a2025-08-20T02:00:22ZrusPractical Medicine Publishing HouseКлиническая онкогематология1997-69332500-21392018-07-0111321321910.21320/2500-2139-2018-11-3-213-219PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s LymphomaEA Demina0NN Blokhin National Medical Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478During the last two decades individualization of programmed treatment combined with intensified chemotherapy has proven to be effective treatment for the majority of classical Hodgkin’s lymphoma (cHL) patients. However, in 10–30 % of cases relapses and resistance to therapy still occur. Further intensification of therapy induces toxicity that leads to decrease in overall survival and quality of life. The standard second-line treatment with high-dose chemotherapy (HDCT) and autologous hematopoietic stem cell transplantation (auto-HSCT) allows for the achievement of long-term 5-year progression-free survival only in 50–60 % of patients with relapsed disease and not more than 40–45 % of patients with refractory disease. Approximately 50 % of patients relapse after HDCT and auto-HSCT. The median overall survival of relapsed patients does not exceed 2 years. Allogeneic HSCT improves treatment results to some extent, but is not an optimal strategy in all patients. A search for new treatment options has been made to improve effectiveness of relapsed and refractory cHL treatment and to reduce toxicity of highly effective programs. А new CD30-targeted conjugate brentuximab vedotin was developed to use anti-CD30 monoclonal antibodies against a specific marker of tumor Reed-Sternberg cells allowing for the transfer of the highly effective antitumor compound of monomethyl auristatin E directly to tumor cells. This drug showed high effectiveness, although failed to provide a complete solution to the problem. The development of anti-PD1 antibody nivolumab opened up new opportunities for cHL treatment. This paper reviews literature information on pharmacological data and antitumor mechanisms of the drug as well as the results of significant international randomised studies.http://bloodjournal.ru/wp-content/uploads/2018/06/1-5.pdfnivolumabHodgkin’s lymphomarelapseresistancetreatment |
| spellingShingle | EA Demina PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma Клиническая онкогематология nivolumab Hodgkin’s lymphoma relapse resistance treatment |
| title | PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma |
| title_full | PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma |
| title_fullStr | PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma |
| title_full_unstemmed | PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma |
| title_short | PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma |
| title_sort | pd 1 blockade with nivolumab as a new immunotherapy for classical hodgkin s lymphoma |
| topic | nivolumab Hodgkin’s lymphoma relapse resistance treatment |
| url | http://bloodjournal.ru/wp-content/uploads/2018/06/1-5.pdf |
| work_keys_str_mv | AT eademina pd1blockadewithnivolumabasanewimmunotherapyforclassicalhodgkinslymphoma |